Lamers et al. BMC Cancer 2012, 12:285 http://www.biomedcentral.com/1471-2407/12/285 12. Brodeur GM: Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003, 3:203–216. 13. Maris JM, Hogarty MD, Bagatell R, Cohn SL: Neuroblastoma. Lancet 2007, 369:2106–2120. 14. Maris JM: Medical progress: recent advances in neuroblastoma. N Engl J Med 2010, 362:2202–2211. 15. Meyer N, Penn LZ: MYC - TIMELINE Reflecting on 25 years with MYC. Nat Rev Cancer 2008, 8:976–990. 16. Chen YY, Takita J, Choi YL, Kato M, Ohira M, Sanada M, Wang LL, Soda M, Kikuchi A, Igarashi T, et al: Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008, 455:971–974. 17. George RE, Sanda T, Hanna M, Frohling S, Luther W, Zhang JM, Ahn Y, Zhou WJ, London WB, McGrady P, et al: Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008, 455:975–978. 18. Janoueix-Lerosey I, Lequin D, Brugieres L, Ribeiro A, de Pontual L, Combaret V, Raynal V, Puisieux A, Schleiermacher G, Pierron G, et al: Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008, 455:967–970. 19. Janoueix-Lerosey I, Schleiermacher G, Delattre O: Molecular pathogenesis of peripheral neuroblastic tumors. Oncogene 2010, 29:1566–1579. 20. Mosse YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, Laquaglia MJ, Sennett R, Lynch JE, Perri P, et al: Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008, 455:930–935. 21. De Brouwer S, De Preter K, Kumps C, Zabrocki P, Porcu M, Westerhout EM, Lakeman A, Vandesompele J, Hoebeeck J, Van Maerken T, et al: Meta- analysis of Neuroblastomas Reveals a Skewed ALK Mutation Spectrum in Tumors with MYCN Amplification. Clin Cancer Res 2010, 16:4353–4362. 22. Van Maerken T, Ferdinande L, Taildeman J, Lambertz I, Yigit N, Vercruysse L, Rihani A, Michaelis M, Cinatl J, Cuvelier CA, et al: Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53. J Natl Cancer Inst 2009, 101:1562–1574. 23. van Noesel MM, Versteeg R: Pediatric neuroblastomas: genetic and epigenetic 'Danse Macabre'. Gene 2004, 325:1–15. 24. Adida C, Berrebi D, Peuchmaur M, Reyes-Mugica M, Altieri DC: Anti- apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet 1998, 351:882–883. 25. Islam A, Kageyama H, Takada N, Kawamato T, Takayasu H, Isogai E, Ohira M, Hashizume K, Kobayashi H, Kaneko Y, et al: High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 2000, 19:617–623. 26. Lamers F, van der Ploeg I, Schild L, Ebus ME, Koster J, Hansen BR, Koch T, Versteeg R, Caron HN, Molenaar JJ: Knockdown of Survivin (BIRC5) causes Apoptosis in Neuroblastoma via Mitotic Catastrophe. Endocr Relat Cancer 2011, 18:657–668. 27. Giaccone G, Zatloukal P, Roubec J, Floor K, Musil J, Kuta M, van Klaveren RJ, Chaudhary S, Gunther A, Shamsili S: Multicenter Phase II Trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. J Clin Oncol 2009, 27:4481–4486. 28. Lamers F, Schild L, Koster J, Versteeg R, Caron H, Molenaar J: Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression. Eur J Cancer 2012, 48(5):763–771. 29. Lewis KD, Samlowski W, Ward J, Catlett J, Cranmer L, Kirkwood J, Lawson D, Whitman E, Gonzalez R: A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma. Invest New Drugs 2011, 29(1):161–166. 30. Nakahara T, Takeuchi M, Kinoyama I, Minematsu T, Shirasuna K, Matsuhisa A, Kita A, Tominaga F, Yamanaka K, Kudoh M, et al: YM155, a novel small- molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 2007, 67:8014–8021. 31. Satoh T, Okamoto I, Miyazaki M, Morinaga R, Tsuya A, Hasegawa Y, Terashima M, Ueda S, Fukuoka M, Ariyoshi Y, et al: Phase I Study of YM155, a novel survivin suppressant, in patients with advanced solid tumors. Clin Cancer Res 2009, 15:3872–3880. 32. Tolcher AW, Mita A, Lewis LD, Garrett CR, Till E, Daud AI, Patnaik A, Papadopoulos K, Takimoto C, Bartels P, et al: Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin. J Clin Oncol 2008, 26:5198–5203. Page 10 of 10 33. Lamers F, Schild L, den Hartog IJM, Ebus ME, Westerhout EM, Ora I, Koster J, Versteeg R, Caron HN, Molenaar JJ: Targeted BCL2 inhibition effectively inhibits Neuroblastoma tumor growth. Eur J Cancer, in press. 34. Santo EE, Ebus ME, Koster J, Schulte JH, Lakeman A, van Sluis P, Vermeulen J, Gisselsson D, Ora I, Lindner S, et al: Oncogenic activation of FOXR1 by 11q23 intrachromosomal deletion-fusions in neuroblastoma. Oncogene 2012, 31(12):1571–1581. 35. Molenaar JJ, Ebus ME, Koster J, van Sluis P, van Noesel CJM, Versteeg R, Caron HN: Cyclin D1 and CDK4 activity contribute to the undifferentiated phenotype in neuroblastoma. Cancer Res 2008, 68:2599–2609. 36. Fix A, Lucchesi C, Ribeiro A, Lequin D, Pierron G, Schleiermacher G, Delattre O, Janoueix-Lerosey I: Characterization of amplicons in neuroblastoma: high-resolution mapping using DNA microarrays, relationship with outcome, and identification of overexpressed genes. Genes Chromosomes Cancer 2008, 47:819–834. 37. Mullenbach R, Lagoda PJL, Welter C: An efficient salt-chloroform extraction of dna from blood and tissues. Trends Genet 1989, 5:391. 38. Ren JY, Shi MG, Liu RS, Yang QH, Johnson T, Skarnes WC, Du CY: The Birc6 (Bruce) gene regulates p53 and the mitochondrial pathway of apoptosis and is essential for mouse embryonic development. Proc Natl Acad Sci USA 2005, 102:565–570. 39. Basu A, Adkins B, Basu C: Down-regulation of caspase-2 by rottlerin via protein kinase c-delta-independent pathway. Cancer Res 2008, 68:2795–2802. 40. Nutt LK, Margolis SS, Jensen M, Herman CE, Dunphy WG, Rathmell JC, Kornbluth S: Metabolic regulation of oocyte cell death through the CaMKII-mediated phosphorylation of caspase-2. Cell 2005, 123:89–103. 41. Shen J, Vakifahmetoglu H, Stridh H, Zhivotovsky B, Wiman KG: PRIMA-1 (MET) induces mitochondrial apoptosis through activation of caspase-2. Oncogene 2008, 27:6571–6580. 42. Wolf M, Korja M, Karhu R, Edgren H, Kilpinen S, Ojala K, Mousses S, Kallioniemi A, Haapasalo H: Array-based gene expression, CGH and tissue data defines a 12q24 gain in neuroblastic tumors with prognostic implication. BMC Cancer 2010, 10:181. 43. Lestini BJ, Goldsmith KC, Fluchel MN, Liu XY, Chen NL, Goyal B, Pawel BR, Hogarty MD: Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists. Cancer Biol Ther 2009, 8:1587–1595. 44. Kushnareva Y, Newmeyer DD: Bioenergetics and cell death. Mitochondrial Res Transl Med 2010, 1201:50–57. 45. Ekert PG, Silke J, Hawkins CJ, Verhagen AM, Vaux DL: DIABLO promotes apoptosis by removing MIHA/XIAP from processed caspase 9. J Cell Biol 2001, 152:483–490. 46. Teitz T, Wei T, Liu D, Valentine V, Valentine M, Grenet J, Lahti JM, Kidd VJ: Caspase-9 and Apaf-1 are expressed and functionally active in human neuroblastoma tumor cell lines with 1p36 LOH and amplified MYCN. Oncogene 2002, 21:1848–1858. doi:10.1186/1471-2407-12-285 Cite this article as: Lamers et al.: Identification of BIRC6 as a novel intervention target for neuroblastoma therapy. BMC Cancer 2012 12:285. Submit your next manuscript to BioMed Central and take full advantage of: • Convenient online submission • Thorough peer review • No space constraints or color ﬁgure charges • Immediate publication on acceptance • Inclusion in PubMed, CAS, Scopus and Google Scholar • Research which is freely available for redistribution Submit your manuscript at www.biomedcentral.com/submit